Doctor of Podiatric Medicine Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Mark Mendeszoon

Podiatrist, Foot & Ankle Surgery Chardon, OH Doctor of Podiatric Medicine

NPI 1356328538 CMS profile 600713

150 7Th Ave Ste 200, Chardon, OH 44024

Open in the dashboard

General payments

$172,718

329 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$150,000

6 holdings reported · through program year 2025

Research they led as principal investigator

$20,100 paid to institutions, not to them · program year 2020

Through program year 2025, Mark Mendeszoon of Chardon, OH is reported in the CMS Open Payments database as having received $172,718 across 329 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $20,100 in research payments, paid to institutions rather than to them. They also declared ownership or investment interests valued at $150,000 across 6 holdings.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 98th percentile of Podiatrist, Foot & Ankle Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

13 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $9,747 30
2024 General $18,067 57
2023 General $51,967 72
2022 General $23,323 56
2021 General $23,013 46
2020 General $19,304 32
2019 General $27,297 36
2025 Ownership $25,000 1
2024 Ownership $25,000 1
2023 Ownership $25,000 1
2022 Ownership $25,000 1
2021 Ownership $25,000 1
2020 Ownership $25,000 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Mark Mendeszoon
  • Podiatrist, Foot & Ankle Surgery median
  • Middle half of Podiatrist, Foot & Ankle Surgery
  • National median

In program year 2025, general payments to Mark Mendeszoon were reported at $9,747. Among 6,994 Podiatrist, Foot & Ankle Surgery profiles paid that year, the median was $424 and the middle half received between $139 and $1,306.

Show as a table
Year Mark Mendeszoon Podiatrist, Foot & Ankle Surgery median Middle half National median
2019 $27,297 $389 $118–$1,406 $163
2020 $19,304 $191 $62–$691 $114
2021 $23,013 $329 $104–$1,341 $132
2022 $23,323 $419 $125–$1,611 $149
2023 $51,967 $377 $128–$1,164 $160
2024 $18,067 $394 $134–$1,168 $164
2025 $9,747 $424 $139–$1,306 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Orthofix Medical, Inc. $88,291 122 payments
  2. Linvatec Corporation $18,484 26 payments
  3. In2Bones USA, LLC $14,819 14 payments
  4. Royal Biologics $10,559 18 payments
  5. Crossroads Extremity Systems, LLC $9,559 10 payments
  6. Dne LLC $8,984 3 payments
  7. Integra LifeSciences Corporation $5,407 18 payments
  8. MedShape, Inc. $4,990 10 payments
  9. Stryker Corporation $2,153 42 payments
  10. Ascension Orthopedics, Inc. $2,040 5 payments
  11. Other $7,432 61 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $123,133 51 payments
  2. Travel and Lodging $26,944 98 payments
  3. Food and Beverage $9,171 166 payments
  4. Royalty or License $4,599 7 payments
  5. Honoraria $4,000 2 payments
  6. Grant $2,500 1 payment
  7. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $1,971 3 payments
  8. Compensation for serving as faculty or as a speaker for a medical education program $400 1 payment
Products named General payments · program years 2019–2025
  1. TrueLok $35,724 97 payments
  2. JUNIORTHO PLATING SYSTEM $22,078 14 payments
  3. TL-HEX $13,463 10 payments
  4. TrueLok Ring Fixation System $11,307 9 payments
  5. Hercules $10,907 9 payments
  6. GALAXY FIXATION SYSTEM $10,770 2 payments
  7. Veronail Titanium Trochanteric Nail $10,125 1 payment
  8. XCaliber Hybrid Fixator $10,125 1 payment
  9. XCaliber Articulated Ankle Fixator $10,125 1 payment
  10. SEAL $8,984 3 payments
  11. Other $135,268 337 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 12 drugs

Part D claims

370

Median for Podiatry: 160

Drug cost

$3,546

Median for Podiatry: $2,368

Branded share of claims

24.1%

Median for Podiatry: 12.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Pregabalin Generic 24 $1,075
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 71 $535
Gabapentin Generic 36 $407
Doxycycline Monohydrate Generic 27 $367
Betamethasone Valerate Generic 12 $298
Cephalexin Generic 96 $238
Amoxicillin-Clavulanate Potass Amoxicillin/Potassium Clav Brand 18 $153
Amitriptyline Hcl Generic 13 $144
Meloxicam Generic 24 $122
Ammonium Lactate Generic 12 $117

The 10 drugs with the highest cost, of 12 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 14,093 Part D prescribers listed as Podiatry; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 98 billing codes

Paid by Medicare

$111,966

Of which drugs: $175

Medicare patients

422

Average age 74

Services billed

2,931

236 women, 186 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 65%
Diabetes 34%
Ischemic heart disease 32%
Chronic kidney disease 25%
Depression 22%
Heart failure 19%
Atrial fibrillation 19%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, methylprednisolone acetate, 1 mg J1010 Office 20 1,080 $108
Injection, methylprednisolone acetate, 20 mg J1020 Office 12 13 $61

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

1 product · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Qutenza
  • Averitas Pharma Inc. $77
$77 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

329 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Podiatrist, Foot & Ankle Surgery in Ohio

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record